Deferasirox in Patients with Chronic Kidney Disease: Assessing the Potential Benefits and Challenges
Abdulqadir J Nashwan,1 Mohamed A Yassin2 1Nursing Department, Hamad Medical Corporation, Doha, Qatar; 2Department of Medical Oncology/Hematology, National Center for Cancer Care and Research, Hamad Medical Corporation, Doha, QatarCorrespondence: Abdulqadir J Nashwan, Nursing Department, Hamad Medica...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2023-11-01
|
| Series: | Journal of Blood Medicine |
| Subjects: | |
| Online Access: | https://www.dovepress.com/deferasirox-in-patients-with-chronic-kidney-disease-assessing-the-pote-peer-reviewed-fulltext-article-JBM |
| _version_ | 1827631264020037632 |
|---|---|
| author | Nashwan AJ Yassin MA |
| author_facet | Nashwan AJ Yassin MA |
| author_sort | Nashwan AJ |
| collection | DOAJ |
| description | Abdulqadir J Nashwan,1 Mohamed A Yassin2 1Nursing Department, Hamad Medical Corporation, Doha, Qatar; 2Department of Medical Oncology/Hematology, National Center for Cancer Care and Research, Hamad Medical Corporation, Doha, QatarCorrespondence: Abdulqadir J Nashwan, Nursing Department, Hamad Medical Corporation, P.O. Box 3050, Doha, Qatar, Tel +974 40240487 ; +974 66473549, Email anashwan@hamad.qaAbstract: Chronic kidney disease (CKD) is a major global health concern, affecting millions of people worldwide. The progressive decline in kidney function often necessitates renal replacement therapy, such as hemodialysis (HD) or peritoneal dialysis (PD), to maintain a patient’s health. Iron overload, which is common in CKD patients on dialysis, can lead to severe complications, including cardiovascular disease and infections where most of the existing iron chelators are deemed unsuitable due to their suboptimal clearance in patients with compromised renal function, it becomes a significant challenge to effectively manage iron overload. Deferasirox (DFX), an oral iron chelator, has emerged as a promising treatment option for managing iron overload in these patients. However, the use of DFX comes with its unique set of challenges, such as its cost, potential side effects, and the need for close monitoring of patients, as well as the noticeable scarcity of comprehensive and rigorous clinical studies confirming its efficacy and safety of DFX. In this review, we delve into both the promising prospects and the emerging challenges associated with DFX use in managing CKD patients on HD or PD, striving for a comprehensive understanding that informs better clinical practice and patient care.Keywords: CHRONIC kidney disease, Deferasirox, chelating therapy, iron overload, hemodialysis, peritoneal dialysis |
| first_indexed | 2024-03-09T14:19:32Z |
| format | Article |
| id | doaj.art-4abcd34fb41a4a98bde6eedfe9ab494e |
| institution | Directory Open Access Journal |
| issn | 1179-2736 |
| language | English |
| last_indexed | 2024-03-09T14:19:32Z |
| publishDate | 2023-11-01 |
| publisher | Dove Medical Press |
| record_format | Article |
| series | Journal of Blood Medicine |
| spelling | doaj.art-4abcd34fb41a4a98bde6eedfe9ab494e2023-11-28T17:15:53ZengDove Medical PressJournal of Blood Medicine1179-27362023-11-01Volume 1458959488526Deferasirox in Patients with Chronic Kidney Disease: Assessing the Potential Benefits and ChallengesNashwan AJYassin MAAbdulqadir J Nashwan,1 Mohamed A Yassin2 1Nursing Department, Hamad Medical Corporation, Doha, Qatar; 2Department of Medical Oncology/Hematology, National Center for Cancer Care and Research, Hamad Medical Corporation, Doha, QatarCorrespondence: Abdulqadir J Nashwan, Nursing Department, Hamad Medical Corporation, P.O. Box 3050, Doha, Qatar, Tel +974 40240487 ; +974 66473549, Email anashwan@hamad.qaAbstract: Chronic kidney disease (CKD) is a major global health concern, affecting millions of people worldwide. The progressive decline in kidney function often necessitates renal replacement therapy, such as hemodialysis (HD) or peritoneal dialysis (PD), to maintain a patient’s health. Iron overload, which is common in CKD patients on dialysis, can lead to severe complications, including cardiovascular disease and infections where most of the existing iron chelators are deemed unsuitable due to their suboptimal clearance in patients with compromised renal function, it becomes a significant challenge to effectively manage iron overload. Deferasirox (DFX), an oral iron chelator, has emerged as a promising treatment option for managing iron overload in these patients. However, the use of DFX comes with its unique set of challenges, such as its cost, potential side effects, and the need for close monitoring of patients, as well as the noticeable scarcity of comprehensive and rigorous clinical studies confirming its efficacy and safety of DFX. In this review, we delve into both the promising prospects and the emerging challenges associated with DFX use in managing CKD patients on HD or PD, striving for a comprehensive understanding that informs better clinical practice and patient care.Keywords: CHRONIC kidney disease, Deferasirox, chelating therapy, iron overload, hemodialysis, peritoneal dialysishttps://www.dovepress.com/deferasirox-in-patients-with-chronic-kidney-disease-assessing-the-pote-peer-reviewed-fulltext-article-JBMchronic kidney diseasedeferasiroxchelating therapyiron overloadhemodialysisperitoneal dialysis |
| spellingShingle | Nashwan AJ Yassin MA Deferasirox in Patients with Chronic Kidney Disease: Assessing the Potential Benefits and Challenges Journal of Blood Medicine chronic kidney disease deferasirox chelating therapy iron overload hemodialysis peritoneal dialysis |
| title | Deferasirox in Patients with Chronic Kidney Disease: Assessing the Potential Benefits and Challenges |
| title_full | Deferasirox in Patients with Chronic Kidney Disease: Assessing the Potential Benefits and Challenges |
| title_fullStr | Deferasirox in Patients with Chronic Kidney Disease: Assessing the Potential Benefits and Challenges |
| title_full_unstemmed | Deferasirox in Patients with Chronic Kidney Disease: Assessing the Potential Benefits and Challenges |
| title_short | Deferasirox in Patients with Chronic Kidney Disease: Assessing the Potential Benefits and Challenges |
| title_sort | deferasirox in patients with chronic kidney disease assessing the potential benefits and challenges |
| topic | chronic kidney disease deferasirox chelating therapy iron overload hemodialysis peritoneal dialysis |
| url | https://www.dovepress.com/deferasirox-in-patients-with-chronic-kidney-disease-assessing-the-pote-peer-reviewed-fulltext-article-JBM |
| work_keys_str_mv | AT nashwanaj deferasiroxinpatientswithchronickidneydiseaseassessingthepotentialbenefitsandchallenges AT yassinma deferasiroxinpatientswithchronickidneydiseaseassessingthepotentialbenefitsandchallenges |